Weekly Cardiology Research Analysis
This week’s cardiology literature highlights a mix of therapeutic progress, advanced prognostic imaging, and rigorous negative trials refining treatment pathways. A phase 3 RCT showed acoramidis reduces mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy, offering a clear practice-impacting therapy. Multimodal AI applied to routine CT attenuation correction plus perfusion markedly improved mortality prediction, signaling scalable prognostic tools. A carefully des
Summary
This week’s cardiology literature highlights a mix of therapeutic progress, advanced prognostic imaging, and rigorous negative trials refining treatment pathways. A phase 3 RCT showed acoramidis reduces mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy, offering a clear practice-impacting therapy. Multimodal AI applied to routine CT attenuation correction plus perfusion markedly improved mortality prediction, signaling scalable prognostic tools. A carefully designed enrichment RCT found macitentan ineffective in HFpEF/HFmrEF with pulmonary vascular disease, narrowing therapeutic targets and emphasizing phenotype-driven trials.
Selected Articles
1. Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.
The phase 3 ATTRibute-CM double-blind RCT randomized patients with ATTR-CM 2:1 to acoramidis 800 mg twice daily vs placebo for 30 months. In the modified ITT population (n≈611), acoramidis reduced the composite of all-cause mortality or first cardiovascular hospitalization (35.9% vs 50.5%; HR 0.64) and reduced first CV hospitalization alone (HR 0.60). Event curves separated early (by month 3) and benefits persisted through 30 months with favorable tolerability.
Impact: Provides definitive, double-blind phase 3 evidence that a disease-modifying oral TTR stabilizer reduces mortality/CV hospitalization in ATTR-CM, directly changing standards of care and payer decisions.
Clinical Implications: Consider routine use of acoramidis in eligible ATTR-CM patients to reduce early and sustained risk of cardiovascular hospitalization and death; implement standard monitoring per amyloidosis care protocols.
Key Findings
- Reduced composite of all-cause mortality or first CV hospitalization (35.9% vs 50.5%; HR 0.64).
- Reduced first cardiovascular hospitalization alone (26.7% vs 42.6%; HR 0.60).
- Early separation of event curves by month 3 and sustained benefit through 30 months with favorable tolerability.
2. Holistic AI analysis of hybrid cardiac perfusion images for mortality prediction.
In a multicenter cohort of 10,480 patients, an AI model integrating CT attenuation correction radiomics, coronary calcium, epicardial fat measures, perfusion, stress test and clinical features achieved an AUC of 0.80 for all-cause mortality — outperforming coronary calcium or perfusion alone. The study demonstrates that routinely acquired CTAC contains rich prognostic signals that can be automatically extracted and combined with perfusion data to improve risk stratification.
Impact: Demonstrates scalable prognostic enhancement by extracting latent anatomic/pathologic features from routinely acquired CTAC images and integrating them with MPI, potentially changing hybrid MPI reporting and downstream management.
Clinical Implications: Hybrid MPI workflows could adopt automated CTAC radiomics extraction to generate decision-ready mortality risk scores, informing intensity of follow-up and preventive strategies without additional scanning burden.
Key Findings
- Integrated AI model achieved AUC 0.80 for all-cause mortality prediction (multimodal: MPI+CT+stress+clinical).
- Model outperformed coronary calcium (AUC 0.64) and perfusion alone (AUC 0.62) with p<0.001.
- Multi-structure segmentation and radiomics across CTAC unlocked prognostic signals beyond conventional metrics.
3. Macitentan for Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Pulmonary Vascular Disease: Results of the SERENADE Randomized Clinical Trial and Open-Label Extension Study.
SERENADE was a randomized, double-blind, multicenter enrichment trial that screened and excluded patients prone to fluid retention via sequential run-ins before randomization. Among 142 randomized patients with LVEF ≥40% and pulmonary vascular disease, macitentan did not reduce NT-proBNP at 24 weeks nor improve KCCQ or time to worsening HF through 52 weeks. The trial’s negative result refines expectations for endothelin receptor antagonism in this HF phenotype.
Impact: A high-quality, phenotype-enriched RCT showing no biomarker or clinical benefit establishes a clear boundary for endothelin receptor antagonist use in HFpEF/HFmrEF with pulmonary vascular disease and guides future trial designs.
Clinical Implications: Do not adopt macitentan routinely for HFpEF/HFmrEF with pulmonary vascular disease; prioritize alternative mechanism-focused or phenotype-guided approaches and continue rigorous hemodynamic phenotyping in trials.
Key Findings
- No reduction in NT-proBNP at 24 weeks (geometric mean ratio ~1.02).
- No improvement in patient-reported KCCQ or time to worsening HF through 52 weeks.
- Enrichment run-ins excluded many patients (230 enrolled → 142 randomized), demonstrating feasibility but ultimately a neutral/negative result.